The Province and Ministry Co-sponsored Collaborative Innovation, Center for Medical Epigenetics, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, P. R. China.
Chembiochem. 2022 Apr 5;23(7):e202200086. doi: 10.1002/cbic.202200086. Epub 2022 Mar 10.
DNA interstrand crosslinks (ICLs) are highly toxic DNA lesions, and induce cell death by blocking DNA strand separation. Most ICL agents aiming to kill cancer cells, also generate adverse side effects to normal cells. H O -inducible DNA ICL agents are highly selective for targeting cancer cells, as the concentration of H O is higher in cancer cells than normal cells. Previous studies have focused on arylboronate-based precursors, reacting with H O to generate reactive quinone methides (QMs) crosslinking DNA. Here we explore phenyl selenide-based precursors 1-3 as H O -inducible DNA ICL agents. The precursors 1-3 can be activated by H O to generate the good benzylic leaving group and promote production of reactive QMs to crosslink DNA. Moreover, the DNA cross-linking ability is enhanced by the introduction of substituents in the para-position of the phenolic hydroxyl group. From the substituents explored (H, OMe, F), the introduction of electron donating group (OMe) shows a pronounced elevating effect. Further mechanistic studies at the molecular and DNA levels confirm alkylation sites located mainly at dAs, dCs and dGs in DNA. Additionally, cellular experiments reveal that agents 1-3 exhibit higher cytotoxicity toward H1299 human lung cancer cells compared to clinically used drugs, by inducing cellular DNA damage, apoptosis and G0/G1 cell cycle arrest. This study provides a strategy to develop H O -inducible DNA interstrand cross-linkers.
DNA 链间交联 (ICLs) 是高度有毒的 DNA 损伤,通过阻断 DNA 链分离导致细胞死亡。大多数旨在杀死癌细胞的 ICL 试剂也会对正常细胞产生不良副作用。HO 诱导的 DNA ICL 试剂对靶向癌细胞具有高度选择性,因为癌细胞中的 HO 浓度高于正常细胞。以前的研究集中在芳基硼酸酯为基础的前体,与 HO 反应生成活性醌甲醚 (QM) 交联 DNA。在这里,我们探索了基于苯基硒的前体 1-3 作为 HO 诱导的 DNA ICL 试剂。前体 1-3 可被 HO 激活,生成良好的苄基离去基团,并促进活性 QM 的生成以交联 DNA。此外,通过在酚羟基的对位引入取代基,可增强 DNA 交联能力。在所探索的取代基(H、OMe、F)中,引入供电子基团(OMe)具有显著的提升作用。分子和 DNA 水平的进一步机制研究证实,烷基化位点主要位于 DNA 中的 dAs、dCs 和 dGs。此外,细胞实验表明,与临床使用的药物相比,试剂 1-3 通过诱导细胞 DNA 损伤、细胞凋亡和 G0/G1 细胞周期停滞,对 H1299 人肺癌细胞表现出更高的细胞毒性。这项研究为开发 HO 诱导的 DNA 链间交联剂提供了一种策略。